Rocuronium vs Succinylcholine for ECT: A Critical Audit of Safety and Speed

The combination of rocuronium and sugammadex (RS) represents a feasible, low-side-effect alternative to the traditional succinylcholine (SCC) for muscle relaxation during psychiatric treatment. However, displacing SCC has proven historically difficult due to its unmatched kinetic profile; for decades, clinicians have tolerated its adverse effects simply because no other agent offered such rapid onset and offset for high-throughput procedures.

Evaluating Rocuronium vs Succinylcholine for ECT

The core inquiry of this meta-analysis is whether the pharmacological precision of RS can outperform the raw speed of SCC. The comparison of Rocuronium vs Succinylcholine for ECT is not merely about paralysis; it is about the quality of the patient's recovery. The study aggregated data from seven papers, comprising 250 RS observations and 282 SCC sessions. The primary measurements focused on seizure duration and the time required for spontaneous breathing to return.

To understand the operational difference, one must contrast the distinct mechanisms of action employed by these agents. Succinylcholine functions as a depolarising neuromuscular blocker, essentially over-stimulating the muscle receptors to induce paralysis. This 'brute force' activation causes fasciculations—visible muscle twitches—which frequently result in significant post-procedural myalgia. Conversely, rocuronium is a non-depolarising agent that competitively blocks receptors without triggering them. The innovation is not the block, but the reversal: sugammadex acts as a selective relaxant binding agent (SRBA). It chemically encapsulates the rocuronium molecule in the bloodstream, effectively scrubbing it from the neuromuscular junction. While SCC relies on the patient’s own plasma cholinesterase for degradation—a variable biological process—RS relies on this precise chemical chelation, theoretically offering a cleaner exit strategy.

The results paint a mixed picture. In terms of therapeutic efficacy, RS was associated with a longer seizure duration (SMD: 0.43), which is generally desirable in ECT. However, this advantage evaporated when the analysis was restricted strictly to randomised controlled trials, suggesting that observational data may have skewed the initial findings. Epistemically, we must separate the measured reduction in side effects from the inferred efficiency. While the study suggests RS reduces myalgia, the data on recovery times was statistically insignificant (P = 0.277).

Furthermore, the analysis revealed massive heterogeneity (I² = 89%–93%) regarding recovery outcomes. This statistical noise likely stems from inconsistent dosing protocols across the included studies. Until large-scale randomised trials standardise the dosage of sugammadex, the predictability of this method remains inferior to the known risks of succinylcholine.